With 2,1 million women being diagnosed with breast cancer (BC) and 626 679 women dying of BC in 2018, there is a significant need to improve therapy in BC1. Triple negative breast cancer (TNBC) is a sub-type of BC characterized by the absence of the estrogen receptor (ER) and progesterone receptor (PR) and without HER2 overexpression and displaying an aggressive clinical behavior2. Currently, chemotherapy remains the main therapeutic option for TNBC patients, though recently, in a subclass of patients harboring germline BRCA1/2 mutations, targeted therapy with Poly (ADP-ribose) polymerase inhibitors (PARPi) Olaparib and Talazoparib has been approved2,3. BRCA1 and BRCA2 are two genes involved in the homologous repair (HR) of double stranded DNA breaks which, when not functional, increase the risk for defective DNA repair and consequent cancer development. The defective HR sensitizes the cells to blocking of alternative DNA repair pathways by PARPi3. Next to their use in patients with HR defects in their tumor, PARPi have also shown efficacy in patients without HR deficiency4,5. Nevertheless, patients treated with PARPi still relapse, highlighting the need to investigate novel combination strategies for the treatment of TNBC3.
|Effective start/end date||1/10/21 → 30/09/25|
- PARP inhibitors
- tumor dendritic cell compartment
- breast cancer
Flemish discipline codes
- Other medical and health sciences not elsewhere classified